War Zone Complicates Roll‑Out of Ebola Vaccine Latest Outbreak Comes Amid Fighting in the Eastern Democratic Republic of the Congo

Total Page:16

File Type:pdf, Size:1020Kb

War Zone Complicates Roll‑Out of Ebola Vaccine Latest Outbreak Comes Amid Fighting in the Eastern Democratic Republic of the Congo NEWS IN FOCUS PUBLISHING Rise of Unpaywall BIOMEDICINE Gene-silencing PHYSICS LHC particle hunters PUBLIC HEALTH Researchers use transforms open-research technology gets first drug embrace brute-force virtual worlds to tackle the landscape p.290 approval p.291 approach p.293 opioid epidemic p.295 DAI KUROKAWA/EPA/SHUTTERSTOCK DAI Movement of refugees and fighters in North Kivu is complicating the response by aid workers to an Ebola outbreak. PUBLIC HEALTH War zone complicates roll-out of Ebola vaccine Latest outbreak comes amid fighting in the eastern Democratic Republic of the Congo. BY AMY MAXMEN The virus is spreading in North Kivu and “The situation is volatile,” says Ibrahima Ituri, in the east of the Democratic Republic of Socé-Fall, director of emergency operations id workers in the Democratic Republic the Congo (DRC). As of 12 August, 57 people for the World Health Organization (WHO) in of the Congo began giving an experi- had shown symptoms of Ebola — including Africa, based in Brazzaville in the neighbour- mental Ebola vaccine to health work- 41 who had died. But violence perpetuated ing Republic of Congo. Aers on 8 August — one week after the World by more than 100 armed groups fighting over Even so, in addition to dispensing the Health Organization declared an outbreak of resources in those lush, green provinces has vaccine, researchers are preparing to give the virus. First responders and public-health escalated this year ahead of a presidential elec- people with Ebola experimental antibody staff are scrambling to contain the outbreak tion scheduled for December. This is the DRC’s treatments and anti viral drugs. while planning how to distribute the vaccine to tenth Ebola outbreak since 1976, but it is the Socé-Fall says that at least 2,000 doses of the communities in the middle of a conflict zone. first in this tumultuous eastern region. experimental vaccine, called rVSV-ZEBOV, ©2018 Spri nger Nature Li mited. All ri ghts reserved. 16 AUGUST 2018 | VOL 560 | NATURE | 289 NEWS IN FOCUS remain in the country from the most recent Ebola outbreak, which ended in July, and more doses are on the way. The DRC will need a larger vaccine supply now, because the strategy deployed during the previous outbreak will not work for the current one. During the previous outbreak — which lasted three months — officials vaccinated health workers, people who had had direct contact with someone with Ebola and the contacts of those contacts. But the instabil- ity in North Kivu and Ituri has made track- ing such connections difficult. In towns where people have been infected but offi- cials can’t track down their contacts, work- ers might vaccinate the entire community instead, says Socé-Fall. An inability to track these connections worries epidemiologists because people Jason Priem (left) and Heather Piwowar co-founded Impactstory, which launched Unpaywall in 2016. on the move spread the virus. Humanitar- ian groups estimate that this year, nearly DATA ACCESS 750,000 people in North Kivu and Ituri have fled from militia fighters. And about one million refugees displaced from their homes by the violence over at least the The rise and rise past decade continue to travel frequently between cities in the region. Some refugees migrate to neighbouring countries such as Uganda, Rwanda and Burundi. of Unpaywall Aid agencies must now consider how to get into these conflict zones to fight Ebola without endangering their staff. Workers Non-profit is a gift to many academics — and tie-ins with might travel with armed security escorts established scientific search engines could broaden its reach. provided by the DRC government for their protection, said Peter Salama, the WHO’s head of emergency preparedness and BY HOLLY ELSE is now at researchers’ fingertips. These deals response, at a press briefing on 3 August. are also enabling funders, librarians and oth- But a key organization fighting Ebola in fter being kicked out of a hotel confer- ers to study open-access publishing trends the area, Médecins Sans Frontières (MSF, ence room where they had participated comprehensively for the first time. also known as Doctors Without Borders), in a three-day, open-science workshop “Unpaywall is a groundbreaking develop- hesitates to use that approach. The group Aand hackathon, a group of computer scientists ment,” says Alberto Martín-Martín, who studies feels that travelling with armed escorts simply moved to an adjacent hallway. There, bibliometrics and science communication at the hinders its ability to help people of various Heather Piwowar, Jason Priem and Cristhian University of Grenada in Spain. “It takes us one political affiliations, says Salha Issoufou, the Parra worked all night on software to help aca- step closer to achieving a true open research head of MSF’s operation in DRC. So MSF demics see how much of their work was freely infrastructure.” BRIAN GLANZ/OPEN SCIENCE FED./CC BY will forgo the escorts. available on the Internet. They realized how After participating in the 2011 hackathon, The next phase of the response by the much time had passed only when they noticed Piwowar and Priem founded a non-profit WHO, the DRC government and aid hotel staff starting to prepare for breakfast. organization called Impactstory, in Vancouver, groups will be to use experimental drugs That all-nighter, back in 2011, laid the foun- Canada, where they to treat people who have Ebola. A national dation for Unpaywall. This free service locates “Unpaywall is a refined Unpaywall. review board that evaluates research eth- open-access articles and presents paywalled groundbreaking (Parra is now a con- ics has approved the use of these treat- papers that have been legally archived and are development. It sultant at the World ments, and Steve Ahuka, a virologist at the freely available on other websites to users who takes us one step Bank in Asunción, National Institute for Biomedical Research might otherwise have hit a paywalled version. closer to a true Paraguay.) based in Kinshasa, says that some therapeu- Since one part of the technology was released open research Research by Priem tics have just arrived in the region. in 2016, the service has become indispensa- infrastructure.” and Piwowar pub- One treatment is an antibody called ble for many researchers. And firms that run lished as a preprint mAb114, which was manufactured by established scientific search engines are start- in August 2017 — using Unpaywall, natu- the US government. Others include the ing to make good use of Unpaywall. rally — suggests that almost half of the recent antiviral drugs Favipiravir (T-705), made On 26 July, Elsevier announced plans to research papers that people search for online by Japanese company Toyama Chemical, integrate Unpaywall into its Scopus database are available for free (H. Piwowar et al. Pre- and Remdesivir (GS-5734), produced by searches, allowing it to deliver millions more print at PeerJ Preprints https://doi.org/10.7287/ Gilead, based in Foster City, California. free-to-read papers to users than it does cur- peerj.preprints.3119v1; 2017). But, says Priem, “Thanks to our experience from the rently. Scopus’s embrace of Unpaywall, along “there is a terrific gap between the availability previous outbreak, we are prepared,” says with similar moves by other search engines, and discoverability” of these papers, and it is this Ahuka. ■ means that much more open-access content problem that Unpaywall hopes to solve. 290 | NATURE | VOL 560 | 16 AUGUST 2018 ©2018 Spri nger Nature Li mited. All ri ghts reserved. ©2018 Spri nger Nature Li mited. All ri ghts reserved. .
Recommended publications
  • COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
    antibiotics Article An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan Sayer Al-Azzam 1, Nizar Mahmoud Mhaidat 1, Hayaa A. Banat 2, Mohammad Alfaour 2, Dana Samih Ahmad 2, Arno Muller 3, Adi Al-Nuseirat 4 , Elizabeth A. Lattyak 5, Barbara R. Conway 6,7 and Mamoon A. Aldeyab 6,* 1 Clinical Pharmacy Department, Jordan University of Science and Technology, Irbid 22110, Jordan; [email protected] (S.A.-A.); [email protected] (N.M.M.) 2 Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan; [email protected] (H.A.B.); [email protected] (M.A.); [email protected] (D.S.A.) 3 Antimicrobial Resistance Division, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland; [email protected] 4 World Health Organization Regional Office for the Eastern Mediterranean, Cairo 11371, Egypt; [email protected] 5 Scientific Computing Associates Corp., River Forest, IL 60305, USA; [email protected] 6 Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, UK; [email protected] 7 Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield HD1 3DH, UK * Correspondence: [email protected] Citation: Al-Azzam, S.; Mhaidat, N.M.; Banat, H.A.; Alfaour, M.; Abstract: Coronavirus disease 2019 (COVID-19) has overlapping clinical characteristics with bacterial Ahmad, D.S.; Muller, A.; Al-Nuseirat, respiratory tract infection, leading to the prescription of potentially unnecessary antibiotics. This A.; Lattyak, E.A.; Conway, B.R.; study aimed at measuring changes and patterns of national antimicrobial use for one year preceding Aldeyab, M.A.
    [Show full text]
  • Tuesday, September 24, 2019 Time: 6:00Pm – 8:00Pm Location: Delegates Dining Room (Private Dining Rooms 6 – 8) Please Email [email protected] to RSVP
    The World Health Organization, the United Nations Development Programme and the Global Fund are pleased to invite you to a Side-Event to the High-Level Meeting on Universal Health Coverage: Anti-Corruption, Transparency and Accountability in Health. A multi-sectoral panel discussion will explore the impact of corruption on achieving Sustainable Development Goal (SDG) 3, ensuring healthy lives and promoting wellbeing for all, with a specific focus on SDG 3.8, achieving universal health coverage (UHC). The discussion will consider how the ongoing establishment of an Anti-Corruption, Transparency and Accountability for Health Alliance (ACTA) can leverage its multi-stakeholder platform to foster coordination and collaboration, provide normative guidance to assist countries in developing strategies and partnerships to prevent health sector corruption, and contribute to interventions that strengthen the global pledge to leave no one behind. Date: Tuesday, September 24, 2019 Time: 6:00pm – 8:00pm Location: Delegates Dining Room (Private Dining Rooms 6 – 8) Please email [email protected] to RSVP. Due to limited seating, please confirm your attendance no later than Thursday, 19 September 2019. AGNÉS SOUCAT Director for Health Systems, Governance and Financing World Health Organization MANDEEP DHALIWAL DR. PETER SALAMA MARIJKE WIJNROKS Director of HIV, Health and Executive Director, Universal Health Coverage Chief of Staff Development Practice Life Course The Global Fund United Nations Development Programme World Health Organization JILLIAN KOHLER ALLAN MALECHE Professor, Leslie Dan Faculty of Pharmacy Executive Director University of Toronto KELIN DIWA SAMAD WILLIAM SAVEDOFF Deputy Minister of Policy and Planning Senior Fellow Ministry of Public Health Center for Global Development Afghanistan Mandeep Dhaliwal Director, HIV, Health and Development Team, Bureau of Policy and Programme Support United Nations Development Programme Mandeep Dhaliwal is the Director of UNDP’s HIV, Health and Development Group, Bureau of Policy and Programme Support.
    [Show full text]
  • Bulletin of the World Health Organization
    News WHO’s new emergencies programme bridges two worlds Peter Salama tells Fiona Fleck how the World Health Organization’s (WHO) new emergencies programme is changing the way the agency helps countries prepare for and respond to health crises. Q: WHO’s new health emergencies programme aims to create one single Peter Salama is leading the World Health Organization’s programme, with one workforce, one (WHO) efforts to reform its emergency work. He was budget, one set of rules and processes appointed Executive Director of WHO’s new Health and one clear line of authority. How Emergencies Programme at the level of Deputy will you do this with WHO’s governance Director-General last year. Before that, he held senior structure of seven entities: headquarters posts at the United Nations Children’s Fund (UNICEF) (HQ) plus six Regional Offices? including Regional Director for the Middle East and A: The programme has one work- North Africa, Global Coordinator for Ebola and Chief of force – and that is the critical point – one WHO set of people we can rely on in emergen- Peter Salama Global Health. Before joining UNICEF in 2002, Salama cies, whether they are at regional level was an epidemic intelligence service officer at the or at HQ, and, increasingly, we want International Emergency and Refugee Health Branch of the United States the heads of Country Offices to see Centers for Disease Control and Prevention, and a visiting professor in nutrition themselves as an integral part of the at Tufts University in the United States of America. He has worked with Médecins programme with the same philosophy, Sans Frontières and Concern Worldwide in Asia and sub-Saharan Africa.
    [Show full text]
  • Ebola: Democratic Republic of Congo
    CRS INSIGHT Ebola: Democratic Republic of Congo Updated October 4, 2018 (IN10917) | Related Author Tiaji Salaam-Blyther | Tiaji Salaam-Blyther, Coordinator, Specialist in Global Health ([email protected], 7-7677) Monyai L. Chavers, Research Assistant ([email protected], 7-0829) On August 1, 2018, the World Health Organization (WHO) reported that a new Ebola outbreak was detected in the eastern part of the Democratic Republic of Congo (DRC), about one week after having declared that a separate outbreak had ended in the western part of the country. This new outbreak is occurring in North Kivu and Ituri provinces, the most populated provinces in DRC, where a humanitarian crisis affecting over 1 million displaced people is ongoing. Health workers have begun vaccinating people in the districts to control the spread of the disease, though armed conflict in the areas is complicating control efforts. As of October 2, 2018, 162 people have contracted Ebola in North Kivu and Ituri provinces (including 19 health workers), 106 of whom have died (3 of whom were health workers). This outbreak is the 10th Ebola outbreak in DRC since the disease was discovered in 1976, and it stands in stark contrast to the previous outbreak (Figure 1). The outbreak that began in May 2018 was contained and ended within two months after having infected 54 people, including 33 of whom died. In its second month, this outbreak has caused twice as many deaths and is continuing to spread. Issues complicating efforts to contain the current outbreak include the following: Conflict. In September 2018, clashes between rebels and government forces had forced WHO to temporarily suspend operations in Beni, the WHO operational base.
    [Show full text]
  • Determining Ribavirin's Mechanism of Action Against Lassa Virus Infection
    www.nature.com/scientificreports OPEN Determining Ribavirin’s mechanism of action against Lassa virus infection Received: 28 March 2017 Paola Carrillo-Bustamante1, Thi Huyen Tram Nguyen2,3, Lisa Oestereich4,5, Stephan Accepted: 4 August 2017 Günther4,5, Jeremie Guedj 2,3 & Frederik Graw1 Published: xx xx xxxx Ribavirin is a broad spectrum antiviral which inhibits Lassa virus (LASV) replication in vitro but exhibits a minor effect on viremiain vivo. However, ribavirin significantly improves the disease outcome when administered in combination with sub-optimal doses of favipiravir, a strong antiviral drug. The mechanisms explaining these conflicting findings have not been determined, so far. Here, we used an interdisciplinary approach combining mathematical models and experimental data in LASV-infected mice that were treated with ribavirin alone or in combination with the drug favipiravir to explore different putative mechanisms of action for ribavirin. We test four different hypotheses that have been previously suggested for ribavirin’s mode of action: (i) acting as a mutagen, thereby limiting the infectivity of new virions; (ii) reducing viremia by impairing viral production; (iii) modulating cell damage, i.e., by reducing inflammation, and (iv) enhancing antiviral immunity. Our analysis indicates that enhancement of antiviral immunity, as well as effects on viral production or transmission are unlikely to be ribavirin’s main mechanism mediating its antiviral effectiveness against LASV infection. Instead, the modeled viral kinetics suggest that the main mode of action of ribavirin is to protect infected cells from dying, possibly reducing the inflammatory response. Lassa fever (LF) is a severe and often fatal hemorrhagic disease caused by Lassa virus (LASV), a member of the Arenaviridae virus family.
    [Show full text]
  • Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
    RESEARCH ARTICLE Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir Ana I. de AÂ vila1, Isabel Gallego1,2, Maria Eugenia Soria3, Josep Gregori2,3,4, Josep Quer2,3,5, Juan Ignacio Esteban2,3,5, Charles M. Rice6, Esteban Domingo1,2*, Celia Perales1,2,3* 1 Centro de BiologõÂa Molecular ªSevero Ochoaº (CSIC-UAM), Consejo Superior de Investigaciones CientõÂficas (CSIC), Campus de Cantoblanco, 28049, Madrid, Spain, 2 Centro de InvestigacioÂn BiomeÂdica en Red de Enfermedades HepaÂticas y Digestivas (CIBERehd), Barcelona, Spain, 3 Liver Unit, Internal Medicine, Laboratory of Malalties Hepàtiques, Vall d'Hebron Institut de Recerca-Hospital Universitari Vall d a11111 ÂHebron, (VHIR-HUVH), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain, 4 Roche Diagnostics, S.L., Sant Cugat del ValleÂs, Spain, 5 Universitat AutoÂnoma de Barcelona, Barcelona, Spain, 6 Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, United States of America * [email protected] (ED); [email protected] (CP) OPEN ACCESS Abstract Citation: de AÂvila AI, Gallego I, Soria ME, Gregori J, Quer J, Esteban JI, et al. (2016) Lethal Lethal mutagenesis is an antiviral approach that consists in extinguishing a virus by an Mutagenesis of Hepatitis C Virus Induced by excess of mutations acquired during replication in the presence of a mutagen. Here we Favipiravir. PLoS ONE 11(10): e0164691. show that favipiravir (T-705) is a potent mutagenic agent for hepatitis C virus (HCV) during doi:10.1371/journal.pone.0164691 its replication in human hepatoma cells. T-705 leads to an excess of G ! A and C ! U tran- Editor: Ming-Lung Yu, Kaohsiung Medical sitions in the mutant spectrum of preextinction HCV populations.
    [Show full text]
  • The GAVI Alliance
    GLOBAL PROGRAM REVIEW The GAVI Alliance Global Program Review The World Bank’s Partnership with the GAVI Alliance Main Report and Annexes Contents ABBREVIATIONS .................................................................................................................................. V ACKNOWLEDGMENTS ........................................................................................................................ XI PROGRAM AT A GLANCE: THE GAVI ALLIANCE ............................................................................ XII KEY BANK STAFF RESPONSIBLE DURING PERIOD UNDER REVIEW ........................................ XIV GLOSSARY ......................................................................................................................................... XV OVERVIEW ........................................................................................................................................ XVII GAVI ALLIANCE MANAGEMENT RESPONSE .............................................................................. XXV WORLD BANK GROUP MANAGEMENT RESPONSE ................................................................... XXIX CHAIRPERSON’S SUMMARY ......................................................................................................... XXXI 1. THE WORLD BANK-GAVI PARTNERSHIP AND THE PURPOSE OF THE REVIEW ...................... 1 Evolution of GAVI .....................................................................................................................................................
    [Show full text]
  • Antiviral Efficacy of Ribavirin and Favipiravir Against Hantaan Virus
    microorganisms Communication Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus Jennifer Mayor 1,2, Olivier Engler 2 and Sylvia Rothenberger 1,2,* 1 Institute of Microbiology, University Hospital Center and University of Lausanne, CH-1011 Lausanne, Switzerland; [email protected] 2 Spiez Laboratory, Federal Office for Civil Protection, CH-3700 Spiez, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +41-213145103 Abstract: Ecological changes, population movements and increasing urbanization promote the expansion of hantaviruses, placing humans at high risk of virus transmission and consequent diseases. The currently limited therapeutic options make the development of antiviral strategies an urgent need. Ribavirin is the only antiviral used currently to treat hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan virus (HTNV), even though severe side effects are associated with this drug. We therefore investigated the antiviral activity of favipiravir, a new antiviral agent against RNA viruses. Both ribavirin and favipiravir demonstrated similar potent antiviral activity on HTNV infection. When combined, the efficacy of ribavirin is enhanced through the addition of low dose favipiravir, highlighting the possibility to provide better treatment than is currently available. Keywords: Hantaan virus; ribavirin; favipiravir; combination therapy Citation: Mayor, J.; Engler, O.; Rothenberger, S. Antiviral Efficacy of 1. Introduction Ribavirin and Favipiravir against Orthohantaviruses (hereafter referred to as hantaviruses) are emerging negative- Hantaan Virus. Microorganisms 2021, strand RNA viruses associated with two life-threatening diseases: hemorrhagic fever with 9, 1306. https://doi.org/10.3390/ renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS). Old World microorganisms9061306 hantaviruses, including the prototypic Hantaan virus (HTNV) and Seoul virus (SEOV) are widespread in Asia where they can cause HFRS with up to 15% case-fatality.
    [Show full text]
  • Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews
    Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews RAPID REVIEW – July 13th 2020. (The information included in this review reflects the evidence as of the date posted in the document. Updates will be developed according to new available evidence) Disclaimer This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. Yet, recognizing that there are numerous ongoing clinical studies, PAHO will periodically update these reviews and corresponding recommendations as new evidence becomes available. 1 Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews Take-home messages thus far: • More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. In this review we examined 26 therapeutic options. • Preliminary findings from the RECOVERY Trial showed that low doses of dexamethasone (6 mg of oral or intravenous preparation once daily for 10 days) significantly reduced mortality by one- third in ventilated patients and by one fifth in patients receiving oxygen only. The anticipated RECOVERY Trial findings and WHO’s SOLIDARITY Trial findings both show no benefit via use of hydroxychloroquine and lopinavir/ritonavir in terms of reducing 28-day mortality or reduced time to clinical improvement or reduced adverse events. • Currently, there is no evidence of benefit in critical outcomes (i.e. reduction in mortality) from any therapeutic option (though remdesivir is revealing promise as one option based on 2 randomized controlled trials) and that conclusively allows for safe and effective use to mitigate or eliminate the causative agent of COVID-19.
    [Show full text]
  • The Exacerbation of Ebola Outbreaks by Conflict in the Democratic Republic of the Congo
    The exacerbation of Ebola outbreaks by conflict in the Democratic Republic of the Congo Chad R. Wellsa,1, Abhishek Pandeya,1, Martial L. Ndeffo Mbahb, Bernard-A. Gaüzèrec, Denis Malvyc,d,e, Burton H. Singerf,2, and Alison P. Galvania aCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT 06520; bDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843; cCentre René Labusquière, Department of Tropical Medicine and Clinical International Health, University of Bordeaux, 33076 Bordeaux, France; dDepartment for Infectious and Tropical Diseases, University Hospital Centre of Bordeaux, 33075 Bordeaux, France; eINSERM 1219, University of Bordeaux, 33076 Bordeaux, France; and fEmerging Pathogens Institute, University of Florida, Gainesville, FL 32610 Contributed by Burton H. Singer, September 9, 2019 (sent for review August 14, 2019; reviewed by David Fisman and Seyed Moghadas) The interplay between civil unrest and disease transmission is not recombinant vesicular stomatitis virus–Zaire Ebola virus vaccine well understood. Violence targeting healthcare workers and Ebola (13). The vaccination campaign not only played an important treatment centers in the Democratic Republic of the Congo (DRC) role in curtailing the epidemic expeditiously (14), it also facili- has been thwarting the case isolation, treatment, and vaccination tated public awareness of the disease and improved practice of efforts. The extent to which conflict impedes public health re- Ebola safety precautions (15). By contrast, the sociopolitical sponse and contributes to incidence has not previously been crisis in eastern DRC has hampered the contact tracing that is a evaluated.
    [Show full text]
  • Ebola Virus Infection: Overview and Update on Prevention and Treatment
    Wayne State University Eugene Applebaum College of Pharmacy and Department of Pharmacy Practice Health Sciences 9-12-2015 Ebola Virus Infection: Overview and Update on Prevention and Treatment Miguel J. Martínez Universitat de Barcelona Abdulbaset M. Salim Wayne State University Juan C. Hurtado Universitat de Barcelona Paul E. Kilgore Wayne State University, [email protected] Follow this and additional works at: https://digitalcommons.wayne.edu/pharm_practice Part of the Epidemiology Commons, International Public Health Commons, and the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Martínez, M.J., Salim, A.M., Hurtado, J.C. et al. Ebola Virus Infection: Overview and Update on Prevention and Treatment. Infect Dis Ther 4, 365–390 (2015). https://doi.org/10.1007/s40121-015-0079-5 This Article is brought to you for free and open access by the Eugene Applebaum College of Pharmacy and Health Sciences at DigitalCommons@WayneState. It has been accepted for inclusion in Department of Pharmacy Practice by an authorized administrator of DigitalCommons@WayneState. Infect Dis Ther (2015) 4:365–390 DOI 10.1007/s40121-015-0079-5 REVIEW Ebola Virus Infection: Overview and Update on Prevention and Treatment Miguel J. Martı´nez • Abdulbaset M. Salim • Juan C. Hurtado • Paul E. Kilgore To view enhanced content go to www.infectiousdiseases-open.com Received: July 30, 2015 / Published online: September 12, 2015 Ó The Author(s) 2015. This article is published with open access at Springerlink.com ABSTRACT Complete and using the search terms Ebola, Ebola virus disease, Ebola hemorrhagic fever, In 2014 and 2015, the largest Ebola virus West Africa outbreak, Ebola transmission, disease (EVD) outbreak in history affected Ebola symptoms and signs, Ebola diagnosis, large populations across West Africa.
    [Show full text]
  • Ebola Virus Disease Outbreak in North Kivu and Ituri Provinces, Democratic Republic of the Congo – Second Update
    RAPID RISK ASSESSMENT Ebola virus disease outbreak in North Kivu and Ituri Provinces, Democratic Republic of the Congo – second update 21 December 2018 Main conclusions As of 16 December 2018, the Ministry of Health of the Democratic Republic of Congo (DRC) has reported 539 Ebola virus disease (EVD) cases, including 48 probable and 491 confirmed cases. This epidemic in the provinces of North Kivu and Ituri is the largest outbreak of EVD recorded in DRC and the second largest worldwide. A total of 315 deaths occurred during the reporting period. As of 16 December 2018, 52 healthcare workers (50 confirmed and two probable) have been reported among the confirmed cases, and of these 17 have died. As of 10 December 2018, the overall case fatality rate was 58%. Since mid-October, an average of around 30 new cases has been reported every week, with 14 health zones reporting confirmed cases in the past 21 days. This trend shows that the outbreak is continuing across geographically dispersed areas. Although the transmission intensity has decreased in Beni, the outbreak is continuing in Butembo city, and new clusters are emerging in the surrounding health zones. A geographical extension of the outbreak (within the country and to neighbouring countries) cannot be excluded as it is unlikely that it will be controlled in the near future. Despite significant achievements, the implementation of response measures remains problematic because of the prolonged humanitarian crisis in North Kivu province, the unstable security situation arising from a complex armed conflict and the mistrust of affected communities in response activities.
    [Show full text]